PanGenomic Health Expands NaraCare.AI Platform with Launch of DNA Testing Program
(TheNewswire)
Vancouver, British Columbia, Canada,October 20, 2025 – TheNewswire - PanGenomic Health Inc.(“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30)is pleased to announce that it has launched a DNA testing program aspart of its Nara.Care AI platform for personalized wellness.
Working with a leading developer of DNA testingtechnologies, the Company will market its Agenta branded DNA testingkits to health-conscious consumers in Canada as part of an initialroll-out campaign. The Company plans to expand marketing into theUnited States in early 2026.
“We believe consumers are looking for betterinformation about their unique health situation to help guide theirpersonal wellness plans”, said Maryam Marissen, President & CEOof PanGenomic Health. “The foundation of our NaraCare.AI platform ispersonalization, and there is no better baseline for that foundationthan incorporating the unique genetic makeup of eachindividual.”
The Agenta DNA tests will deliver significant data intothe Nara.Care AI platform that uses leading AI models to provideactionable insights into diet, fitness, metabolism, brain function andoverall health and wellness. Given the sensitivity of genomic data,the Company will implement appropriate safeguards to protect theprivacy of all health data.
The Agenta DNA testing kits will be available forpurchase this quarter on the Agenta Health eCommerce site, which canbe accessed at www.agentahealth.store.
About PanGenomic Health
PanGenomic Health is a precision health company thathas developed a self-care digital platform to deliver personalized,evidence-based information about natural treatments. Registered as aBritish Columbia benefit company, PanGenomic Health's mission isto promote alternative health solutions tailored to the health profileof each individual. To learn more about PanGenomic Health’s productsand services: www.pangenomic.com or email:info@pangenomic.com.
For more information, please contact:
Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 305 5369
fair@fairfax.partners
This news release includes certainstatements that may be deemed “forward-looking statements”,including statements respecting the services to be provided byPanGenomic Health and the consideration to be paid to PanGenomicHealth. The use of any of the words “anticipate”, “continue”,“estimate”, “expect”, “may”, “will”, “would”,“project”, “should”, “believe”, “plans” and similarexpressions are intended to identify forward looking statements.Although PanGenomic Health believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because PanGenomic Health can give no assurance that theywill prove to be correct. Since forward-looking statements addressfuture events and conditions, by their very nature they involve inherentrisks and uncertainties. These statements speak only as of the date ofthis News Release. Actual results could differ materially from thosecurrently anticipated due to a number of factors and risks includingvarious risk factors discussed in PanGenomic Health’s disclosuredocuments which can be found under PanGenomic Health’s profile onwww.sedarplus.ca. These risk factors include the possibility of delays inPanGenomic Health’s development or product launch efforts,PanGenomic Health not having sufficient financial resources tocomplete its development or product launch efforts in a timely mannerand other risks, including those that may be outside of the control ofPanGenomic Health. Except as required under applicable securitieslegislation, PanGenomic Health undertakes no obligation to publiclyupdate or revise forward-looking statements.
The Canadian Securities Exchange hasneither approved nor disapproved the information contained herein anddoes not accept responsibility for the adequacy or accuracy of thisnews release.
Copyright (c) 2025 TheNewswire - All rights reserved.
